Jan Terje Andersen

• Akbar, Rahmad; Robert, Philippe Paul Auguste; Weber, Cédric R.; Widrich, Michael; Frank, Robert & Pavlovic, Milena [Show all 19 contributors for this article] (2022). In silico proof of principle of machine learning-based antibody design at unconstrained scale. mAbs. ISSN 1942-0862. doi: 10.1080/19420862.2022.2031482.
• Grevys, Algirdas; Frick, Rahel; Mester, Simone; Flem-Karlsen, Karine; Nilsen, Jeannette & Foss, Stian [Show all 13 contributors for this article] (2022). Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. iScience. ISSN 2589-0042. 25(2). doi: 10.1016/j.isci.2022.103746.
• Akbar, Rahmad; Bashour, Habib; Rawat, Puneet; Robert, Philippe Paul Auguste; Smorodina, Eva & Cotet, Tudor-Stefan [Show all 15 contributors for this article] (2022). Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. mAbs. ISSN 1942-0862. 14(1). doi: 10.1080/19420862.2021.2008790.
• Sivertsen, Magne S.; Lode, Heidrun Elisabeth; Tollefsrud Gjølberg, Torleif; Petrovski, Goran; Andersen, Jan Terje & Jørstad, Øystein Kalsnes [Show all 7 contributors for this article] (2021). Cluster of symptomatic silicone oil droplets following intravitreal injections: A 1-year observational study. BMJ Open Ophthalmology. ISSN 2397-3269. 6:e000764(1), p. 1–5. doi: 10.1136/bmjophth-2021-000764. Full text in Research Archive
• Azevedo, Cláudia; Pinto, Soraia; Benjakul, Sopisa; Nilsen, Jeannette; Santos, Helder A. & Traverso, Giovanni [Show all 8 contributors for this article] (2021). Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery. Advanced Drug Delivery Reviews. ISSN 0169-409X. 175. doi: 10.1016/j.addr.2021.04.016. Full text in Research Archive
• Christopoulos, Panagiotis; Gjølberg, Torleif Tollefsrud; Krüger, Stig; Haraldsen, Guttorm; Andersen, Jan Terje & Sundlisæter, Eirik (2021). Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases. Frontiers in Immunology. ISSN 1664-3224. 12:668207, p. 1–22. doi: 10.3389/fimmu.2021.668207. Full text in Research Archive
• Azevedo, Cláudia; Andersen, Jan Terje; Traverso, Giovanni & Sarmento, Bruno (2021). The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs. European journal of pharmaceutics and biopharmaceutics. ISSN 0939-6411. 162, p. 99–104. doi: 10.1016/j.ejpb.2021.03.009.
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, Trung; Schikora-Rustad, Stine & Vaage, Eline Benno [Show all 22 contributors for this article] (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. ISSN 0022-3050. doi: 10.1136/jnnp-2021-327612. Full text in Research Archive
• Tunheim, Gro; Rø, Gunnar Øyvind Isaksson; Tran, Trung; Kran, Anne-Marte Bakken; Andersen, Jan Terje & Vaage, Eline Benno [Show all 10 contributors for this article] (2021). Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic. Influenza and Other Respiratory Viruses. ISSN 1750-2640. 16(2), p. 204–212. doi: 10.1111/irv.12932. Full text in Research Archive
• Merten, Hannes; Brandl, Fabian; Zimmermann, Martina; Schaefer, Jonas V.; Irpinio, Linda & Sand, Kine M.K. [Show all 10 contributors for this article] (2021). Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. European journal of pharmaceutics and biopharmaceutics. ISSN 0939-6411. 167, p. 104–113. doi: 10.1016/j.ejpb.2021.07.011. Full text in Research Archive
• Mester, Simone; Evers, Mitchell; Meyer, Saskia; Nilsen, Jeannette; Greiff, Victor & Sandlie, Inger [Show all 8 contributors for this article] (2021). Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo. mAbs. ISSN 1942-0862. 13:1893888(1), p. 1–14. doi: 10.1080/19420862.2021.1893888. Full text in Research Archive
• Mandrup, Ole A.; Ong, Sui Ching; Lykkemark, Simon; Dinesen, Anders; Rudnik-Jansen, Imke & Dagnæs-Hansen, Niels Frederik [Show all 9 contributors for this article] (2021). Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Communications Biology. ISSN 2399-3642. 4:310(1), p. 1–11. doi: 10.1038/s42003-021-01790-2. Full text in Research Archive
• Lombardi, Silvia; Hovden Aaen, Kristin; Nilsen, Jeannette; Ferrarese, Mattia; Tollefsrud Gjølberg, Torleif & Bernardi, Francesco [Show all 9 contributors for this article] (2021). Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity. British Journal of Haematology. ISSN 0007-1048. 194(2), p. 453–462. doi: 10.1111/bjh.17559. Full text in Research Archive
• Høydahl, Lene; Frigstad, Terje; Rasmussen, Ingunn B; Øynebråten, Inger; Schjetne, Karoline W & Andersen, Jan Terje [Show all 10 contributors for this article] (2021). Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses. Vaccine. ISSN 0264-410X. 39(11), p. 1583–1592. doi: 10.1016/j.vaccine.2021.02.012. Full text in Research Archive
• Caddy, Sarah L.; Vaysburd, Marina; Papa, Guido; Wing, Mark; O'Connell, Kevin & Stoycheva, Diana [Show all 10 contributors for this article] (2020). Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO Journal. ISSN 0261-4189. 40:e106228(5), p. 1–9. doi: 10.15252/embj.2020106228. Full text in Research Archive
• Schrottmaier, Waltraud C.; Salzmann, Manuel; Badrnya, Sigrun; Mussbacher, Marion; Kral-Pointer, Julia B. & Morava, Susanne [Show all 17 contributors for this article] (2020). Platelets mediate serological memory to neutralize viruses in vitro and in vivo. Blood Advances. ISSN 2473-9529. 4(16), p. 3971–3976. doi: 10.1182/bloodadvances.2020001786. Full text in Research Archive
• Hovden Aaen, Kristin; Anthi, Aina Karen; Sandlie, Inger; Nilsen, Jeannette; Mester, Simone & Andersen, Jan Terje (2020). The neonatal Fc receptor in mucosal immune regulation. Scandinavian Journal of Immunology. ISSN 0300-9475. doi: 10.1111/sji.13017.
• Nilsen, Jeannette; Trabjerg, Esben; Grevys, Algirdas; Azevedo, Claudia; Brennan, Stephen O. & Stensland, Maria [Show all 14 contributors for this article] (2020). An intact C-terminal end of albumin is required for its long half-life in humans. Communications Biology. ISSN 2399-3642. 3(1). doi: 10.1038/s42003-020-0903-7. Full text in Research Archive
• Hubbard, Jonathan J.; Pyzik, Michal; Rath, Timo; Kozicky, Lisa K.; Sand, Kine Marita Knudsen & Gandhi, Amit K. [Show all 17 contributors for this article] (2020). FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity. Journal of Experimental Medicine (JEM). ISSN 0022-1007. 217(10). doi: 10.1084/jem.20200359.
• Caddy, Sarah L.; Vaysburd, Marina; Wing, Mark; Foss, Stian; Andersen, Jan Terje & O'Connell, Kevin [Show all 11 contributors for this article] (2020). Intracellular neutralisation of rotavirus by VP6-specific IgG. PLoS Pathogens. ISSN 1553-7366. 16:e1008732(8), p. 1–18. doi: 10.1371/journal.ppat.1008732. Full text in Research Archive
• Azevedo, Claudia; Nilsen, Jeanette; Grevys, Algirdas; Nunes, Rute; Andersen, Jan Terje & Sarmento, Bruno (2020). Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin . Journal of Controlled Release. ISSN 0168-3659. doi: 10.1016/j.jconrel.2020.08.005.
• Holter, Jan Cato; Pischke, Soeren; de Boer, Eline; Lind, Andreas; Jenum, Synne & Holten, Aleksander Rygh [Show all 32 contributors for this article] (2020). Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients . Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 117(40), p. 25018–25025. doi: 10.1073/pnas.2010540117. Full text in Research Archive
• Bern, Malin C.; Nilsen, Jeannette; Ferrarese, Mattia; Sand, Kine Marita Knudsen; Tollefsrud Gjølberg, Torleif & Lode, Heidrun Elisabeth [Show all 24 contributors for this article] (2020). An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Science Translational Medicine. ISSN 1946-6234. 12(565), p. 1–13. doi: 10.1126/scitranslmed.abb0580. Full text in Research Archive
• Lau, Corinna; McAdam, Martin Berner; Bergseth, Grete; Grevys, Algirdas; Bruun, Jack-Ansgar & Ludviksen, Judith K [Show all 11 contributors for this article] (2019). NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. mAbs. ISSN 1942-0862. 12:e1686319(1), p. 1–13. doi: 10.1080/19420862.2019.1686319. Full text in Research Archive Show summary

  The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled validation of IgG2/4 antibody functions. Here, we describe the design of a recombinant control antibody (NHDL), which was generated by combining the variable light (VL) and heavy (VH) chains from two unrelated specificities. NHDL was readily expressed and purified as a stable IgG2/4 antibody, and showed no detectable specificity toward any putative antigen present in human or porcine blood. The approach of artificial VL/VH combination may be adopted for the design of other recombinant control antibodies.

• Lode, Heidrun Elisabeth; Gjølberg, Torleif Tollefsrud ; Foss, Stian; Sivertsen, Magne S.; Brustugun, Jørgen & Andersson, Yvonne [Show all 9 contributors for this article] (2019). A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Scientific Reports. ISSN 2045-2322. 9:18021(1), p. 1–10. doi: 10.1038/s41598-019-54226-7. Full text in Research Archive Show summary

  Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. The diseases are chronic in their nature, and most patients need long-term therapy to suppress disease activity. We previously reported a compounding method for repackaging and storage of aflibercept (Eylea), a commonly used anti-VEGF biologic, in silicone oil-coated plastic syringes without compromising drug stability or activity. In addition to improving safety and time spent per patient, compounding of anti-VEGF biologics enables single-dose vials to be split into multiple syringes, thereby considerably reducing waste and drug expenses. However, symptomatic silicone oil droplets may deposit in the eye's vitreous body after repetitive injections. To fully avoid this complication, we here report on a novel pharmaceutical compounding method using silicone oil-free syringes and a 33 G × 9 mm Low Dead Space Needle hub injection needle. We evaluate the method for three anti-VEGF biologics commonly used in ophthalmology: aflibercept, ranibizumab (Lucentis) and bevacizumab (Avastin). Our results show that compounding and storage for one week does not compromise the functional activity of the biologics and allows for safe and cost-effective compounding of anti-VEGF biologics for intravitreal injections in prefilled silicone oil-free syringes.

• Blumberg, Laurence J.; Humphries, John E.; Jones, Susan Dana; Pearce, L. Bruce; Holgate, Robert G.E. & Hearn, Arron R. [Show all 23 contributors for this article] (2019). Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Science Advances. ISSN 2375-2548. 5:eaax9586(12), p. 1–13. doi: 10.1126/sciadv.aax9586. Full text in Research Archive
• Foss, Stian; Bottermann, Maria; Jonsson, Alexandra; Sandlie, Inger; James, Leo C. & Andersen, Jan Terje (2019). TRIM21-From intracellular immunity to therapy. Frontiers in Immunology. ISSN 1664-3224. 10:2049, p. 1–14. doi: 10.3389/fimmu.2019.02049. Full text in Research Archive
• Maaland, Astri Fjelde; Heyerdahl, Helen; O'Shea, Adam; Eiriksdóttir, Bergthora; Pascal, Veronique & Andersen, Jan Terje [Show all 8 contributors for this article] (2019). Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003. European Journal of Nuclear Medicine and Molecular Imaging. ISSN 1619-7070. 46(11), p. 2311–2321. doi: 10.1007/s00259-019-04417-1. Full text in Research Archive
• Labzin, LI; Bottermann, M; Rodriguez-Silvestre, P; Foss, Stian; Andersen, Jan Terje & Vaysburd, M [Show all 8 contributors for this article] (2019). Antibody and DNA sensing pathways converge to activate the inflammasome during primary human macrophage infection. EMBO Journal. ISSN 0261-4189. doi: 10.15252/embj.2018101365. Full text in Research Archive
• Bottermann, Maria; Foss, Stian; Caddy, Sarah L.; Clift, Dean; van Tienen, Laurens M. & Vaysburd, Marina [Show all 16 contributors for this article] (2019). Complement C4 prevents viral infection through capsid inactivation. Cell Host and Microbe. ISSN 1931-3128. 25(4), p. 617–629. doi: 10.1016/j.chom.2019.02.016. Full text in Research Archive
• Pyzik, Michal; Sand, Kine Marita Knudsen; Hubbard, Jonathan J.; Andersen, Jan Terje; Sandlie, Inger & Blumberg, Richard S. (2019). The neonatal Fc Receptor (FcRn): A misnomer? Frontiers in Immunology. ISSN 1664-3224. 10:1540(JULY), p. 1–24. doi: 10.3389/fimmu.2019.01540. Full text in Research Archive
• Shaw, Alan; Hoffecker, Ian T.; Smyrlaki, Ioanna; Rosa, João; Grevys, Algirdas & Bryant-Bratlie, Diane Lynn [Show all 10 contributors for this article] (2019). Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies. Nature Nanotechnology. ISSN 1748-3387. 14(2), p. 184–190. doi: 10.1038/s41565-018-0336-3.
• Nilsen, Jeannette; Bern, Malin C.; Sand, Kine Marita Knudsen; Grevys, Algirdas; Dalhus, Bjørn & Sandlie, Inger [Show all 7 contributors for this article] (2018). Human and mouse albumin bind their respective neonatal Fc receptors differently. Scientific Reports. ISSN 2045-2322. 8:14648, p. 1–12. doi: 10.1038/s41598-018-32817-0. Full text in Research Archive
• Bottermann, Maria; Foss, Stian; van Tienen, Laurens M.; Vaysburd, Marina; Cruickshank, James & O’Connell, Kevin [Show all 16 contributors for this article] (2018). TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 115(41), p. 10440–10445. doi: 10.1073/pnas.1806314115. Full text in Research Archive
• Grevys, Algirdas; Nilsen, Jeannette; Sand, Kine Marita Knudsen; Daba, Muluneh Bekele; Øynebråten, Inger & Bern, Malin C. [Show all 15 contributors for this article] (2018). A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nature Communications. ISSN 2041-1723. 9. doi: 10.1038/s41467-018-03061-x. Full text in Research Archive
• Sivertsen, Magne S.; Jørstad, Øystein Kalsnes; Grevys, Algirdas; Foss, Stian; Moe, Morten Carsten & Andersen, Jan Terje (2018). Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties. Scientific Reports. ISSN 2045-2322. 8(1). doi: 10.1038/s41598-018-20525-8. Full text in Research Archive
• Stapleton, Nigel M.; Armstrong-Fisher, Sylvia S.; Andersen, Jan Terje; van der Schoot, C. Ellen; Porter, Charlene & Page, Kenneth R. [Show all 12 contributors for this article] (2018). Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport. Molecular Immunology. ISSN 0161-5890. 95, p. 1–9. doi: 10.1016/j.molimm.2018.01.006. Full text in Research Archive
• Nilsen, Jeannette; Sandlie, Inger; Roopenian, Derry C. & Andersen, Jan Terje (2018). Animal models for evaluation of albumin-based therapeutics. Current Opinion in Chemical Engineering. ISSN 2211-3398. 19, p. 68–76. doi: 10.1016/j.coche.2017.11.007. Full text in Research Archive
• Pyzik, Michal; Rath, Timo; Kuo, Timothy T.; Win, Sanda; Baker, Kristi & Hubbard, Jonathan J. [Show all 24 contributors for this article] (2017). Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 114(14), p. E2862–E2871. doi: 10.1073/pnas.1618291114. Full text in Research Archive
• Bottermann, Maria; Lode, Heidrun Elisabeth; Watkinson, Ruth E.; Foss, Stian; Sandlie, Inger & Andersen, Jan Terje [Show all 7 contributors for this article] (2017). Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity. Scientific Reports. ISSN 2045-2322. doi: 10.1038/srep45418. Full text in Research Archive
• Cardoso, Ines Do Rosario; Østerlund, Eva Christina; Stamnæs, Jorunn; Iversen, Rasmus; Andersen, Jan Terje & Jørgensen, Thomas J D [Show all 7 contributors for this article] (2017). Dissecting the interaction between transglutaminase 2 and fibronectin. Amino Acids. ISSN 0939-4451. 49(3), p. 489–500. doi: 10.1007/s00726-016-2296-y. Full text in Research Archive
• Bottermann, Maria; Lode, Heidrun Elisabeth; Watkinson, Ruth E; Foss, Stian; Sandlie, Inger & Andersen, Jan Terje [Show all 7 contributors for this article] (2016). Antibody-antigen kinetics constrain intracellular humoral immunity. Scientific Reports. ISSN 2045-2322. 6. doi: 10.1038/srep37457. Full text in Research Archive
• Foss, Stian; Watkinson, Ruth E; Grevys, Algirdas; Mc, Adam Martin Berner; Bern, Malin C. & Høydahl, Lene Støkken [Show all 11 contributors for this article] (2016). TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity. Journal of Immunology. ISSN 0022-1767. 196(8), p. 3452–3459. doi: 10.4049/jimmunol.1502601. Full text in Research Archive
• Foss, Stian; Grevys, Algirdas; Sand, Kine Marita Knudsen; Bern, Malin C.; Blundell, Pat & Michaelsen, Terje Einar [Show all 9 contributors for this article] (2016). Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization. Journal of Controlled Release. ISSN 0168-3659. 223, p. 42–52. doi: 10.1016/j.jconrel.2015.12.033. Full text in Research Archive
• Foss, Stian; Watkinson, Ruth; Sandlie, Inger; James, Leo C. & Andersen, Jan Terje (2015). TRIM21: A cytosolic Fc receptor with broad antibody isotype specificity. Immunological Reviews. ISSN 0105-2896. 268(1), p. 328–339. doi: 10.1111/imr.12363. Full text in Research Archive
• Xi, Chien; Hnida, Kathrin; Graewert, Melissa Ann; Andersen, Jan Terje; Iversen, Rasmus & Tuukkanen, Anne [Show all 8 contributors for this article] (2015). Structural basis for antigen recognition by transglutaminase 2-specific autoantibodies in celiac disease. Journal of Biological Chemistry. ISSN 0021-9258. 290(35), p. 21365–21375. doi: 10.1074/jbc.M115.669895.
• Cardoso, Ines Do Rosario; Stamnæs, Jorunn; Andersen, Jan Terje; Melino, Gerry; Iversen, Rasmus & Sollid, Ludvig Magne (2015). Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies. The FEBS Journal. ISSN 1742-464X. 282(11), p. 2063–2075. doi: 10.1111/febs.13276.
• Almåsbak, Hilde Kjersti; Walseng, Even; Kristian, Alexandr; Myhre, Marit Renee; Suso, Else Marit Inderberg & Munthe, Ludvig Andre [Show all 11 contributors for this article] (2015). Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Therapy. ISSN 0969-7128. 22(5), p. 391–403. doi: 10.1038/gt.2015.4.
• Grevys, Algirdas; Bern, Malin C.; Foss, Stian; Bratlie, Diane Lynn Bryant; Moen, Anders & Gunnarsen, Kristin Støen [Show all 10 contributors for this article] (2015). Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. Journal of Immunology. ISSN 0022-1767. 194(11), p. 5497–5508. doi: 10.4049/jimmunol.1401218. Full text in Research Archive
• Daniel M, Czajkowsky; Andersen, Jan Terje; Fuchs, Anja; Wilson, Timothy J; Mekhaiel, David & Colonna, Marco [Show all 17 contributors for this article] (2015). Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications. Scientific Reports. ISSN 2045-2322. 5, p. 1–11. doi: 10.1038/srep09526. Full text in Research Archive
• Bern, Malin C.; Sand, Kine Marita Knudsen; Nilsen, Jeannette; Sandlie, Inger & Andersen, Jan Terje (2015). The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. Journal of Controlled Release. ISSN 0168-3659. 211, p. 144–162. doi: 10.1016/j.jconrel.2015.06.006.
• Sand, Kine Marita Knudsen; Bern, Malin C.; Nilsen, Jeannette; Noordzij, Hanna Theodora; Sandlie, Inger & Andersen, Jan Terje (2015). Unraveling the interaction between FcRn and albumin: Opportunities for design of albumin-based therapeutics. Frontiers in Immunology. ISSN 1664-3224. 5:682. doi: 10.3389/fimmu.2014.00682. Full text in Research Archive
• Hallstensen, Randi; Bergseth, Grete; Foss, Stian; Jæger, Steinar; Gedde-Dahl, Thobias & Holt, jan [Show all 14 contributors for this article] (2015). Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. ISSN 0171-2985. 220(4), p. 452–459. doi: 10.1016/j.imbio.2014.11.003. Full text in Research Archive
• Andersen, Jan Terje; Hjelstuen, Ole Kristian & Sandlie, Inger (2014). From Basic Research to Innovation, Medical Technology - Meeting Tomorrow's Health Care Challenges. Novus Forlag. ISSN 978-82-7099-791-6. p. 39–50.
• Sand, Kine Marita Knudsen; Bern, Malin C.; Nilsen, Jeannette; Dalhus, Bjørn; Gunnarsen, Kristin Støen & Cameron, Jason [Show all 10 contributors for this article] (2014). Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc Receptor (FcRn). Journal of Biological Chemistry. ISSN 0021-9258. 289(50), p. 34583–34594. doi: 10.1074/jbc.M114.587675. Full text in Research Archive
• Einarsdottir, Helga K.; Stapleton, Nigel M.; Scherjon, Sicco; Andersen, Jan Terje; Rispens, Theo & van der Schoot, C. Ellen [Show all 7 contributors for this article] (2014). On the perplexingly low rate of transport of IgG2 across the human placenta. PLOS ONE. ISSN 1932-6203. 9(9). doi: 10.1371/journal.pone.0108319.
• Andersen, Jan Terje; Dalhus, Bjørn; Viuff, Dorthe; Ravn, Birgitte Thue; Gunnarsen, Kristin Støen & Plumridge, Andrew [Show all 17 contributors for this article] (2014). Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. Journal of Biological Chemistry. ISSN 0021-9258. 289(19), p. 13492–13502. doi: 10.1074/jbc.M114.549832. Full text in Research Archive
• Sand, Kine Marita Knudsen; Bern, Malin C.; Nilsen, Jeannette; Dalhus, Bjørn; Gunnarsen, Kristin Støen & Cameron, Jason [Show all 10 contributors for this article] (2014). Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc Receptor (FcRn). Journal of Biological Chemistry. ISSN 0021-9258. 289(50), p. 34583–34594. doi: 10.1074/jbc.M114.587675.
• Sand, Kine Marita Knudsen; Dalhus, Bjørn; Christianson, Gregory J.; Bern, Malin C.; Foss, Stian & Cameron, Jason [Show all 11 contributors for this article] (2014). Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. Journal of Biological Chemistry. ISSN 0021-9258. 289(24), p. 17228–17239. doi: 10.1074/jbc.M113.522565. Full text in Research Archive
• Rahman, Mohummad Aminur; Kristiansen, Per Eugen; Veiseth, Silje Veie; Andersen, Jan Terje; Yap, Kyoko L. & Zhou, Ming-Ming [Show all 9 contributors for this article] (2014). The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure. Biochemistry. ISSN 0006-2960. 53(13), p. 2091–2100. doi: 10.1021/bi401436h.
• Jung, Sang Taek; Kelton, William; Kang, Tae Hyun; T.W. Ng, Daphne; Andersen, Jan Terje & Sandlie, Inger [Show all 8 contributors for this article] (2013). Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity. ACS Chemical Biology. ISSN 1554-8929. 8(2), p. 368–375. doi: 10.1021/cb300455f.
• Yazaki, Paul J.; Lee, Brian; Channappal, Divya; Cheung, Chia-Wei; Crow, Desiree & Chea, Junie [Show all 15 contributors for this article] (2013). A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Engineering Design & Selection. ISSN 1741-0126. 26(3), p. 187–193. doi: 10.1093/protein/gzs096.
• Mathiesen, Line; Nielsen, Leif K.; Andersen, Jan Terje; Grevys, Algirdas; Sandlie, Inger & Michaelsen, Terje Einar [Show all 9 contributors for this article] (2013). Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. Blood. ISSN 0006-4971. 122(7), p. 1174–1181. doi: 10.1182/blood-2012-12-473843. Full text in Research Archive
• Lau, Corinna; Gunnarsen, Kristin Støen; Høydahl, Lene Støkken; Andersen, Jan Terje; Berntzen, Gøril & Pharo, Anne Margrethe [Show all 15 contributors for this article] (2013). Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation. Journal of Immunology. ISSN 0022-1767. 191(9), p. 4769–4777. doi: 10.4049/jimmunol.1301653. Full text in Research Archive
• Jacobsen, Johanne Tracey; Gjerstad, Vibeke Sundvold; Skjeldal, Frode Miltzow; Andersen, Jan Terje; Abrahamsen, Greger & Bakke, Oddmund [Show all 8 contributors for this article] (2013). B-cell tolerance to the B-cell receptor variable regions. European Journal of Immunology. ISSN 0014-2980. 43(10), p. 2577–2587. doi: 10.1002/eji.201243203.
• Andersen, Jan Terje; Cameron, J; Plumridge, A; Sleep, D; Evans, L & Sandlie, Inger (2013). Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner: IMPLICATIONS FOR IN VIVO HALF-LIFE EVALUATION OF ALBUMIN FUSION THERAPEUTICS. Journal of Biological Chemistry. ISSN 0021-9258. 288(33), p. 24277–24285. doi: 10.1074/jbc.M113.463000. Full text in Research Archive
• Andersen, Jan Terje; Gonzalez-Pajuelo, Maria; Foss, Stian; Landsverk, Ole J. B.; Pinto, Debora & Szyroki, Alexander [Show all 10 contributors for this article] (2013). Selection of Nanobodies that Target Human Neonatal Fc Receptor. Scientific Reports. ISSN 2045-2322. 3. doi: 10.1038/srep01118. Full text in Research Archive
• Andersen, Jan Terje; Foss, Stian; Kenanova, Vania E; Olafsen, Tove; Leikfoss, Ingvild Sørum & Roopenian, Derry C [Show all 8 contributors for this article] (2012). Anti-carcinoembryonic Antigen Single-chain Variable Fragment Antibody Variants Bind Mouse and Human Neonatal Fc Receptor with Different Affinities That Reveal Distinct Cross-species Differences in Serum Half-life. Journal of Biological Chemistry. ISSN 0021-9258. 287(27), p. 22927–22937. doi: 10.1074/jbc.M112.355131. Full text in Research Archive
• Andersen, Jan Terje; Dalhus, Bjørn; Cameron, Jason; Daba, Muluneh Bekele; Plumridge, Andrew & Evans, Leslie [Show all 11 contributors for this article] (2012). Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nature Communications. ISSN 2041-1723. 3. doi: 10.1038/ncomms1607. Full text in Research Archive
• Stapleton, NM; Andersen, Jan Terje; Stemerding, AM; Bjarnarson, SP; Verheul, RC & Gerritsen, J. [Show all 13 contributors for this article] (2011). Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Communications. ISSN 2041-1723. 2. doi: 10.1038/ncomms1608. Full text in Research Archive Show summary

  Human IgG3 displays the strongest effector functions of all IgG subclasses but has a short half-life for unresolved reasons. Here we show that IgG3 binds to IgG-salvage receptor (FcRn), but that FcRn-mediated transport and rescue of IgG3 is inhibited in the presence of IgG1 due to intracellular competition between IgG1 and IgG3. We reveal that this occurs because of a single amino acid difference at position 435, where IgG3 has an arginine instead of the histidine found in all other IgG subclasses. While the presence of R435 in IgG increases binding to FcRn at neutral pH, it decreases binding at acidic pH, affecting the rescue effi ciency-but only in the presence of H435-IgG. Importantly, we show that in humans the half-life of the H435containing IgG3 allotype is comparable to IgG1. H435-IgG3 also gave enhanced protection against a pneumococcal challenge in mice, demonstrating H435-IgG3 to be a candidate for monoclonal antibody therapies.

• Mekhaiel, David N. A.; Czajkowsky, Daniel M.; Andersen, Jan Terje; Shi, Jianguo; El-Faham, Marwa & Doenhoff, Michael [Show all 12 contributors for this article] (2011). Polymeric human Fc-fusion proteins with modified effector functions. Scientific Reports. ISSN 2045-2322. 1. doi: 10.1038/srep00124. Full text in Research Archive
• Baker, Kristi; Qiao, Shuo Wang; Kuo, Timothy T.; Aveson, Victoria G.; Platzer, Barbara & Andersen, Jan Terje [Show all 12 contributors for this article] (2011). Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8(-)CD11b(+) dendritic cells. Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 108(24), p. 9927–9932. doi: 10.1073/pnas.1019037108.
• Andersen, Jan Terje; Pehrson, Rikard; Tolmachev, Vladimir; Daba, Muluneh Bekele; Abrahamsen, Lars & Ekblad, Caroline (2011). Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain. Journal of Biological Chemistry. ISSN 0021-9258. 286(7), p. 5234–5241. doi: 10.1074/jbc.M110.164848.
• Andersen, Jan Terje; Daba, Muluneh Bekele & Sandlie, Inger (2010). FcRn binding properties of an abnormal truncated analbuminemic albumin variant. Clinical Biochemistry. ISSN 0009-9120. 43(4-5), p. 367–372. doi: 10.1016/j.clinbiochem.2009.12.001.
• Andersen, Jan Terje; Daba, Muluneh Bekele; Berntzen, Gøril; Michaelsen, Terje Einar & Sandlie, Inger (2010). Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. Journal of Biological Chemistry. ISSN 0021-9258. 285(7), p. 4826–4836. doi: 10.1074/jbc.M109.081828. Full text in Research Archive
• Andersen, Jan Terje & Sandlie, Inger (2009). The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation: Implications for Development of New Diagnostics and Therapeutics. Drug Metabolism and Pharmacokinetics (DMPK). ISSN 1347-4367. 24(4), p. 318–332.
• Berntzen, Gøril; Andersen, Jan Terje; Ustgård, Kristine; Ustgård, Kristine; Michaelsen, Terje Einar & Mousavi, Darbi Seyed Ali [Show all 13 contributors for this article] (2009). Identification of a High Affinity Fc gamma RIIA-binding Peptide That Distinguishes Fc gamma RIIA from Fc gamma RIIB and Exploits Fc gamma RIIA-mediated Phagocytosis and Degradation. Journal of Biological Chemistry. ISSN 0021-9258. 284(2), p. 1126–1135. doi: 10.1074/jbc.M803584200. Full text in Research Archive

View all works in Cristin

• Andersen, Jan Terje & Sandlie, Inger (2011). Pharmacokinetics of IgG and albumin: The impact of FcRn for Design of Drug Delivery Systems: The impact of FcRn for Design of Drug Delivery Systems. Wiley-VCH Verlag GmbH. ISBN 9783527328239. 34 p.
• Andersen, Jan Terje & Sandlie, Inger (2011). Extending Antibody Half Lives with Albumin In: Recombinant Antibodies for Immunotherapy. Cambridge University Press. ISBN 9780521887328. 17 p.
• Andersen, Jan Terje; Sandlie, Inger; Kenanova, Vania E; Olafsen, Tove & Wu, Anna M (2010). Engineering of the Fc Region for Improved PK (FcRn interaction. Springer-Verlag Berlin Heidelberg . ISBN 978-3-642-01143-6. 19 p.

View all works in Cristin

• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, The Trung; Schikora-Rustad, Stine & Vaage, Eline Benno [Show all 22 contributors for this article] (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies.
• Grødeland, Gunnveig; Fossum, Even & Andersen, Jan Terje (2020). Vaksinepodden.no: Antistoffer.
• Jørstad, Øystein Kalsnes; Sivertsen, Magne S.; Andersen, Jan Terje & Moe, Morten Carsten (2020). Kan ampullene med covid-19-vaksine utnyttes bedre? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 20.1039. doi: 10.4045/tidsskr.20.1039.
• Andersen, Jan Terje (2020). Fikk Trump en magisk cocktail av antistoffer? Aftenposten Viten. ISSN 2464-3033.
• Andersen, Jan Terje (2019). University of Oslo, IAVI, and THSTI to Develop HIV Broadly Neutralizing Antibodies as a Prevention Product for Affordable Global Access.
• Andersen, Jan Terje (2019). Design of affordable anti-HIV antibodies.
• Andersen, Jan Terje (2019). Langtidsvirkende, forebyggende hiv-medisin.
• Andersen, Jan Terje; Sakya, Siri Aastedatter; Foss, Stian; Sandlie, Inger & Voets, Ardi (2019). Is an HIV vaccine within reach? Vaksinebloggen.
• Andersen, Jan Terje; Sakya, Siri Aastedatter; Foss, Stian & Sandlie, Inger (2019). Hvordan kan moderne medisin forebygge HIV? Medisinbloggen.
• Andersen, Jan Terje & Kalveland, Julie (2019). Får millioner til å forske på hiv. [Newspaper]. Dagens Medisin.
• Andersen, Jan Terje (2019). Antistoffer kan gi ny hiv-medisin. Aftenposten Viten. ISSN 2464-3033.
• Vestrum, Alexander & Andersen, Jan Terje (2019). Norske millioner til forskning på hiv-medisin for kvinner . [Journal]. Bistandsaktuelt.
• Vestrum, Alexander & Andersen, Jan Terje (2019). Millioner til forskning på hiv-medisin for kvinner. [Newspaper]. VG.
• Shaw, Alan; Hoffecker, Ian T.; Smyrlaki, Ioanna; Rosa, João; Grevys, Algirdas & Bryant-Bratlie, Diane Lynn [Show all 10 contributors for this article] (2019). Publisher Correction: Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies. Nature Nanotechnology. ISSN 1748-3387. 14(4), p. 398–398. doi: 10.1038/s41565-019-0404-3.
• Foss, Stian; Michaelsen, Terje Einar; Sandlie, Inger & Andersen, Jan Terje (2011). The Influence of Removal of the IgG Fab Arms on Binding to FcRn. Scandinavian Journal of Immunology. ISSN 0300-9475. 73(4), p. 350–351. doi: 10.1111/j.1365-3083.2011.02516.x.
• Andersen, JT; Daba, Muluneh B; Berntzen, G; Michaelsen, Terje Einar & Sandlie, I (2009). Cross-species binding analyses of mouse and human neonatal Fc receptor with their ligands. Implications for evaluations of therapeutic antibodies and albumin fusions.
• Tunheim, Gro; Kran, Anne-Marte Bakken; Rø, Gunnar Øyvind Isaksson; Hungnes, Olav; Lund-Johansen, Fridtjof & Tran, Trung [Show all 8 contributors for this article] (2020). Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in late summer 2020. Folkehelseinstituttet. ISSN 978-82-8406-155-9. Show summary

  COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2. Infection with SARS-CoV-2 induces antibodies to the virus, therefore the presence of these antibodies in a person’s blood indicates that the person has been infected with SARS-CoV-2. This is the second study measuring antibodies against SARS-CoV-2 in residual serum samples collected systematically from various geographical regions in Norway and covering all age groups. The first study with residual sera from April/May 2020 and August 2019, was published as a report in June 2020 (1). In the present study, a total of 1812 residual sera were sampled from 16 microbiology laboratories from late July to mid-September 2020 (week numbers 30-37). The sera were tested for antibodies against SARS-CoV-2 using a novel in-house assay established at the Department of Immunology, Oslo University Hospital. Based on these measurements, the estimated seroprevalence in the Norwegian population in the late summer was 0.6% [95% credible interval (CrI) 0.2 - 1.2]. This is not significantly different from the seroprevalence estimate based on the 900 samples collected in the spring (1.0% [95% CrI 0.1- 2.4])(1). Antibodies against SARS-CoV-2 were found in samples from 6 of the 11 counties, but there were no significant differences between the seroprevalence estimates for each county. However, the sample size from each county varied considerably (from 20 to 387) and the number of positive samples were limited (11 in total). There were no significant differences between the seroprevalence estimates for the various age groups or between males and females. During the summer of 2020, the pandemic was quite contained in Norway. This may explain why the estimated seroprevalence for the Norwegian population was similar in the spring and in the late summer. In this first follow-up study, more laboratories contributed, and a greater number of samples was tested, leading to better precision of the seroprevalence estimate. New follow-up studies of antibodies against SARS-CoV-2 in future collections of residual sera will provide further information about the development of the COVID-19 pandemic in Norway

• Tunheim, Gro; Kran, Anne-Marte Bakken; Rø, Gunnar Øyvind Isaksson; Steens, Anneke; Hungnes, Olav & Lund-Johansen, Fridtjof [Show all 9 contributors for this article] (2020). Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in April/May 2020 and August 2019. Folkehelseinstituttet. ISSN 978-82-8406-109-2. Show summary

  COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2. Infection with SARS-CoV-2 induces antibodies to the virus, therefore the presence of these antibodies in a person’s blood indicates that the person has been infected with SARS-CoV-2. This is the first study measuring antibodies against SARS-CoV-2 in serum samples collected systematically from various geographical regions in Norway and covering all age groups. A total of 900 residual sera from nine laboratories were sampled in week numbers 17-20, 2020, and tested for antibodies against SARS-CoV-2 using a novel in-house assay established at the Department of Immunology, Oslo University Hospital. Based on these measurements, the estimated seroprevalence in the Norwegian population is probably close to 1% (1.0% (95% credible interval 0.1% - 2.4%)). We did not find any differences in seroprevalence by gender or age group. However, there seem to be geographical differences in the prevalence of seropositive individuals; there was a non-significant trend indicating that the number of positive samples and the estimated seroprevalence was higher in Oslo than in other regions. However, the sample size was limited as not all counties were included, and only an average number of 100 samples have been collected from each laboratory. Therefore, these results should be interpreted with caution. Follow-up studies of antibodies against SARS-CoV-2 in future collections of residual sera can provide further information about the development of the COVID-19 pandemic in Norway.

• Andersen, Jan Terje & Sandlie, Inger (2011). FcRn regulates the pharmacokinetics of albumin. Sojo University Publishing.

View all works in Cristin